<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905602</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1905-101</org_study_id>
    <nct_id>NCT04905602</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administered SHR-1905 in Healthy Subjects and Subjects With Mild Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hengrui Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and&#xD;
      subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability&#xD;
      and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">January 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-last</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to last time point after SHR-1905 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-inf</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity after SHR-1905 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Time to Cmax of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Maximum observed concentration of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL/F</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Apparent clearance of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-V/F</measure>
    <time_frame>Start of Treament to end of study (approximately 16 weeks)</time_frame>
    <description>Apparent volume of distribution during terminal phase of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>Terminal elimination half-life of SHR-1905</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug antibody</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
    <description>The percentage of subjects with positive ADA titers over time for SHR-1905</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1905/placebo</intervention_name>
    <description>Drug: SHR-1905 subcutaneous, single dose&#xD;
Drug: Placebo subcutaneous, single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the trial procedures and possible adverse events, volunteers to&#xD;
             participate in the trial, and provides written informed consent, be able to comply&#xD;
             with all the requirements and able to complete the study.&#xD;
&#xD;
          2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed&#xD;
             consent form.&#xD;
&#xD;
          3. Total body weight â‰¥ 45 kg, body mass index (BMI) between 18 and 28 kg/m2 at screening.&#xD;
&#xD;
          4. For healthy subjects, no clinically significant abnormalities in medical history,&#xD;
             general physical examination, vital signs, laboratory tests (hematology, urinalysis,&#xD;
             blood chemistry, coagulation function and thyroid function) and ECG at the&#xD;
             investigator's discretion during screening and baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known medical history of severe disease in cardiovascular, liver, kidney, digestive&#xD;
             tract, mental, nerve, hematology, metabolic disorders, etc.&#xD;
&#xD;
          2. Severe injuries or major surgeries within 6 months before screening or plan to do&#xD;
             surgeries during the trial.&#xD;
&#xD;
          3. Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency&#xD;
             virus (HIV-Ab) at screening.&#xD;
&#xD;
          4. Hyper/Hypotension which define as Systolic blood pressure (SBP) &gt;140mmHg or &lt;90mmHg,&#xD;
             or Diastolic blood pressure (DBP)&gt;90mmHg or &lt;40mmHg at screening and at check in.&#xD;
&#xD;
          5. Clinically significant abnormalities in 12-Lead ECG (e.g., For male QTcF &gt; 450msec,&#xD;
             for female QTcF &gt; 470msec) at screening and at check in&#xD;
&#xD;
          6. Positive alcohol breath test during baseline visit.&#xD;
&#xD;
          7. Positive nicotine test during screening.&#xD;
&#xD;
          8. Positive urine drug screen during screening.&#xD;
&#xD;
          9. Participation in clinical trials of other investigational drugs or medical devices&#xD;
             within 3 months prior to screening or within 5 half-lives of any drugs during&#xD;
             screening visit, or in the follow-up period of a clinical study whichever is longer&#xD;
             (according to the date of signed consent form) which is defined as have consented and&#xD;
             used other investigational drugs (including placebo) or trial medical devices&#xD;
&#xD;
         10. Any other circumstances that, in the investigator's judgment, may increase the risk to&#xD;
             the subject, or associated with the subject's participation in and completion of the&#xD;
             study or could preclude the evaluation of the subject's response&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyu Yang</last_name>
    <phone>+86 18818211895</phone>
    <email>xiaoyu.yang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo zhu</last_name>
    <phone>+86 13380043088</phone>
    <email>bo.zhu@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yu, Bachelor</last_name>
      <phone>86-21-54030254</phone>
      <email>cyu@shxh-centerlab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

